Autologous Schwann Cell Therapy for Peripheral Nerve Injury
Trial Summary
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Research shows that Schwann cell transplantation can promote nerve regeneration and repair in both peripheral and central nervous systems. Studies have demonstrated improvements in motor and sensory functions in patients with spinal cord injuries after receiving autologous Schwann cell transplants, suggesting potential effectiveness for peripheral nerve injuries as well.
12345Research indicates that autologous Schwann cell therapy is generally safe for humans, as studies have shown no serious adverse effects or complications related to the therapy in patients with spinal cord injuries. Some patients experienced temporary sensations like tingling or muscle spasms, but no long-term safety issues were reported.
13678Autologous Schwann Cell Therapy is unique because it uses the patient's own Schwann cells, which are specialized cells that support nerve repair, to promote healing of peripheral nerve injuries. This approach is different from other treatments as it involves transplanting these cells directly to the injury site, potentially enhancing nerve regeneration and reducing the risk of immune rejection.
234910Eligibility Criteria
This trial is for adults aged 18-65 who have had a severe nerve injury in the past year, such as sciatic or brachial plexus injuries. It's not for pregnant women, those with certain pre-existing conditions, allergies to gentamicin, HIV/Hepatitis B/C, cognitive impairments that prevent consent, or if the nerve gap is over 10 cm.Participant Groups
- Severe Peripheral Nerve Injury (PNI)
- Spinal Cord Injury (SCI)
- Spinal Cord Injury (SCI)